BCL2 like 2Genealiases: BCL-W · BCL2-L-2 · BCLW · PPP1R51
Q-omics provides the consensus-scored BCL2L2 profile across patient tissues and cancer cell-line models. BCL2L2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, BCL2L2 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, BCL2L2 RNA expression shows 20,486 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, THCA, and ACC as cancer lineages where BCL2L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCL2L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCL2L2 survival associations across molecular data types. BCL2L2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCL2L2 RNA expression–survival associations across cancer types. High BCL2L2 expression shows unfavorable associations in HNSC, LIHC, UVM and OV, but favorable associations in KIRC and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for BCL2L2 RNA expression.
This table summarizes BCL2L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for BCL2L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCL2L2 shows lower tumor expression in THCA, LUAD, KIRP, KIRC and BLCA and higher tumor expression in LIHC. The THCA box plot shows higher BCL2L2 RNA expression in normal versus tumor tissue (log2 FC = −0.852, t-test p < 0.001).
This table shows molecular features associated with BCL2L2 in patient tissues and cancer cell lines. In patient samples, BCL2L2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BCL2L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
